AbbVie Inc’s Raised Bid Confirms My Shire PLC Sell Rating

Shire PLC (LON:SHP) shares are sliding following AbbVie Inc (NYSE: ABBV)’s increased bid, confirming this Fool’s previous sell call.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

shireLast Friday, I explained why I thought Shire (LSE: SHP) (NASDAQ: SHPG.US) shareholders should sell their shares, regardless of the possibility of an increased bid from US pharma firm AbbVie.

Earlier today, AbbVie did submit a raised bid — so was I wrong?

I still say sell

AbbVie’s raised bid is for £22.44 in cash and 0.8568 AbbVie shares for each Shire share. This equates to around £51 at today’s exchange rates.

The offer is an 11% increase on the previous £46 proposal, but interestingly, Shire’s share price has not budged following the news — indeed, as I write, Shire share price has started to fall, and is now down by 3% on this morning’s opening price.

What’s happening?

AbbVie claims to have “met with, or spoken to” Shire shareholders who represent the majority of Shire’s outstanding shares.

However, the fact that Shire’s share price has fallen following the new offer seems to suggest that the City doesn’t expect Shire’s management to take up the offer, increasing the chances that the bid will fall through by the 18 July  deadline.

Indeed, having looked at the details of the offer, I can see several problems with AbbVie’s new bid, which could explain the market’s lack of interest.

Not enough cash

Although this deal would have tax advantages for AbbVie, it might not do for Shire’s largest, long-term shareholders, who could face substantial capital gains tax bills.

Less than half the offer is in cash, so large UK shareholders would also be left with a big pile of AbbVie’s US-listed shares. In many cases, UK funds would be forced to sell these US shares straight after the deal went through, which would depress the price of AbbVie shares, reducing the real value of AbbVie’s offer.

Private shareholders in the UK would experience the same problems, and would face US share dealing and foreign exchange costs, too.

In my view, it seems fair to say that the true value of AbbVie’s revised offer, to most shareholders, is likely to be much less than £51.

Challenging valuation

A second problem is that Shire’s current share price places a seriously ambitious valuation on Shire’s business — around 23 times 2014 forecast earnings.

Shire shares trade at a premium of more than 20% to their pre-bid price, and have risen by 450% since 2009. For most shareholders, I think it’s time to take profits, de-risk, and sell — because Shire shares could plummet if the AbbVie bid fails.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Roland does not own shares in any of the companies mentioned in this article. The Motley Fool has recommended shares in Shire.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »